A Multi-Cohort Metabolomics Analysis Discloses Sphingomyelin (32:1) Levels to be Inversely Related to Incident Ischemic Stroke

To search for novel pathophysiological pathways related to ischemic stroke using a metabolomics approach. We identified 204 metabolites in plasma by liquid chromatography mass spectrometry in 3 independent population-based samples (TwinGene, Prospective Investigation of the Vasculature in Uppsala Se...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of stroke and cerebrovascular diseases 2020-02, Vol.29 (2), p.104476-104476, Article 104476
Hauptverfasser: Lind, Lars, Salihovic, Samira, Ganna, Andrea, Sundström, Johan, Broeckling, Corey D., Magnusson, Patrik K., Pedersen, Nancy L., Siegbahn, Agneta, Prenni, Jessica, Fall, Tove, Ingelsson, Erik, Ärnlöv, Johan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To search for novel pathophysiological pathways related to ischemic stroke using a metabolomics approach. We identified 204 metabolites in plasma by liquid chromatography mass spectrometry in 3 independent population-based samples (TwinGene, Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) and Uppsala Longitudinal Study of Adult Men). TwinGene was used for discovery and the other 2 samples were meta-analyzed as replication. In PIVUS, traditional cardiovascular (CV) risk factors, multiple markers of subclinical CV disease, markers of coagulation/fibrinolysis were measured and analyzed in relation to top metabolites. In TwinGene (177 incident cases, median follow-up 4.3 years), levels of 28 metabolites were associated with incident ischemic stroke at a false discover rate (FDR) of 5%. In the replication (together 194 incident cases, follow-up 10 and 12 years, respectively), only sphingomyelin (32:1) was significantly associated (HR .69 per SD change, 95% CI .57-0.83, P value = .00014; FDR
ISSN:1052-3057
1532-8511
1532-8511
DOI:10.1016/j.jstrokecerebrovasdis.2019.104476